Infinimmune selected KBI Biopharma as its manufacturing partner partly because KBI's Celexis cell line is highly portable. This foresight de-risks future global scale-up, ensuring the manufacturing process can be easily transferred to different facilities worldwide, a key consideration for long-term commercialization and partnerships.

Unlike small-molecule drugs, biologics manufacturing cannot be simply scaled up on demand because "the process is the product." A superior manufacturing and supply chain capability is not a back-office function but a key market differentiator that commercial teams must leverage to win customers and outpace competitors.

The build vs. outsource decision is strategic. Building in-house is justified when manufacturing is a core competitive advantage or the process itself is your key IP. Otherwise, outsourcing to a CDMO offers critical speed to clinic and preserves capital.

The sterile fill market isn't monolithic; it's segmented by manufacturing type. High-volume, low-mix products like GLP-1s require different CDMO capabilities than high-mix, lower-volume biologics. The latter demands deep expertise in tech transfer and new product launches, a distinct skill set from routine, high-scale production.

A contract development and manufacturing organization (CDMO) that began as a sponsor company developing its own drugs possesses a unique understanding of the entire asset lifecycle. This "sponsor DNA" enables them to provide more strategic, consultative guidance beyond simply fulfilling a manufacturing contract.

A CDMO that promises a problem-free process without asking tough questions is a red flag. The best partners are those who challenge your assumptions early. This indicates they are engaged and invested in success, rather than being overconfident or apathetic.

Traditional ELISA techniques for biologics are slow and expensive, requiring separate validations for each molecule. Modern mass spectrometry can analyze a mixture of biologics (e.g., six antibodies) in a single, more accurate run, potentially cutting the analytical portion of development costs by 50%.

Teams focus on clinical data for accelerated FDA designations but often underestimate the reality that this forces an equally accelerated timeline for Chemistry, Manufacturing, and Controls (CMC). Manufacturing scale-up, validation, and analytical testing must keep pace with the clinical program to avoid significant delays.

A company's development approach is dictated by its business model. Startups use simple, low-cost methods for quick proof-of-concept data. Large pharma invests in robust, high-throughput systems to de-risk processes for regulatory demands. CDMOs must be flexible to serve both.